Mucosal tolerance to prevent type 1 diabetes: can the outcome be improved in humans?

MediCity Research Laboratory, University of Turku and National Public Health Institute, Tykistökatu 6, FIN-20520 Turku, Finland.
The Review of Diabetic Studies 02/2004; 1(3):113-21. DOI: 10.1900/RDS.2004.1.113
Source: PubMed

ABSTRACT The results of trials in which autoantigens have been fed to individuals affected by autoimmune diseases - multiple sclerosis, rheumatoid arthritis and type 1 diabetes - have been disappointing in terms of clinical improvement. This is in striking contrast to the results in experimental rodent models of these diseases. The outcome of the recent DPT-1 trial testing oral insulin in individuals at risk of type 1 diabetes was also disappointing, in contrast to the effects of oral insulin in the non-obese diabetic (NOD) mouse model of type 1 diabetes. However, it is premature to conclude that mucosal tolerance works only in in-bred rodents and not in humans with autoimmune disease. Except for oral insulin in DPT-1, the human trials were performed in individuals with end-stage disease when this form of immune regulation might not be expected to be effective. Importantly, in no trial was an immune response to the autoantigen documented, to demonstrate that the dose was at least bioavailable. Furthermore, mucosal autoantigen administration is a 'double-edged sword' and in rodents can lead not only to regulatory and protective immunity but also to pathogenic, tissue-destructive immunity and exacerbation of autoimmune disease. When suppression of autoimmune disease is observed it may be because autoantigen was administered under conditions which minimize induction of pathogenic immunity. Thus, clinical protocols for mucosal autoantigen administration may need to be modified to favor induction of regulatory immunity. In this short review, we discuss recent studies in autoimmune diabetes-prone NOD mice indicating that with novel modifications mucosal autoantigen administration could be harnessed to prevent type 1 diabetes in humans.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Immune responses to certain heat-shock proteins (HSP) develop in virtually all inflammatory diseases; however, the significance of such responses is only now becoming clear. In models of experimental arthritis, HSPs can prevent or arrest inflammatory damage, and in initial clinical trials in patients with chronic inflammatory diseases, including rheumatoid arthritis, HSP peptides have been shown to promote the production of anti-inflammatory cytokines, indicating immunoregulatory potential of HSP. Heat shock proteins, also called stress-proteins, are ubiquitous self-antigens that are over-expressed in inflamed tissues. For some reason, the prokaryotic homologous proteins, present in every bacterial species, are dominantly immunogenic. This is striking, especially given the fact that these proteins have large areas of sequence homologies with the host (mammalian) counterparts. Furthermore, in experimental models of arthritis, immunisation with bacterial heat shock proteins has been seen to lead to inhibition of disease development. In addition oral or nasal administration has similarly been seen to lead to disease inhibition. Based on the experimental evidence collected, it becomes attractive to suppose that the exposure to homologues of these self antigens, as present in for instance the bacterial intestinal flora, has a decisive impact on the regulation of self tolerance at the level of T cells. If so, it becomes attractive to use such proteins or their derivative peptides for modulation of inflammation relevant T cells as an antigen specific immunotherapy approach, without the immediate necessity of defining disease specific auto-antigens Keywords:Heat shock proteins-arthritis-T cells-immune regulation
    12/2009: pages 85-101;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Induction of long-term tolerance to β-cell autoantigens has been investigated both in animal models and in human type 1 diabetes (T1D) in order to prevent the disease. As regards external compounds, the dietary plant protein fraction has been associated with high penetrance of the disease, whereas gluten-free diets prevent T1D in animal models. Herewith we investigated whether intranasal (i.n.) administration of gliadin or gluten may arrest the diabetogenic process. I.n. administration of gliadin to 4-week-old NOD mice significantly reduced the diabetes incidence. Similarly, the insulitis was lowered. Intranasal gliadin also rescued a fraction of prediabetic 13-week-old NOD mice from progressing to clinical onset of diabetes compared to OVA-treated controls. Vaccination with i.n. gliadin led to an induction of CD4+Foxp3+ T cells and even more significant induction of γδ T cells in mucosal, but not in non-mucosal lymphoid compartments. This prevention strategy was characterized by an increased proportion of IL-10 and a decreased proportion of IL-2, IL-4 and IFN-γ-positive CD4+Foxp3+ T cells, and IFN-γ-positive γδ T cells, preferentially in mucosal lymphoid organs. In conclusion, i.n. vaccination with gliadin, an environmental antigen with possible etiological influence in T1D, may represent a novel, safer strategy for prevention or even early cure of T1D.
    PLoS ONE 01/2014; 9(4):e94530. · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Oral tolerance designates the status of systemic hyporesponsiveness against an antigen that makes contact with the immune system via the mucosa of the gastrointestinal tract. In various animal models of autoimmune disease the feeding of the particular autoantigen has been shown to tolerize the animal, thereby ameliorating the course of disease. In contrast, effectivity has not been found in human trials to induce oral tolerance in patients suffering from autoimmune disease. However, the underlying mechanisms of tolerance in rodents, in particular the induction of anti-inflammatory cytokines, seem to be functional in humans as well. Studies using the human neoantigen keyhole limpet hemocyanin (KLH) offer experimental access to examine cellular and molecular basics of oral tolerance in humans required to raise the efficiency of oral tolerance induction in clinical trials.
    Experimental and Molecular Pathology 10/2012; · 2.88 Impact Factor

Full-text (2 Sources)

Available from
May 31, 2014